Back to top

crispr: Archive

Sundeep Ganoria

CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?

Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.

VRTXPositive Net Change BEAMPositive Net Change EDITPositive Net Change CRSPPositive Net Change

Zacks Equity Research

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2

Allogene's (ALLO) second-quarter earnings beat estimates but sales miss the mark. It expects to submit a regulatory filing with the FDA for its lead pipeline drug in large B-cell lymphoma indication by 2027.

ALLOPositive Net Change FULCPositive Net Change IMTXNegative Net Change TRDAPositive Net Change